Azilsartan
- TRADE NAME: Edarbi (Takeda)
- INDICATIONS: Hypertension
- CLASS: Angiotensin receptor antagonist (blocker), Antihypertensive
- HALF-LIFE: 11 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
NSAIDs
PREGNANCY CATEGORY: D
category C in first trimester; category D in second and third trimesters
FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 08/29/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric